DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,957 INR | -1.54% |
|
-3.26% | +2.75% |
| Sales 2024 * | 279B 3.34B | Sales 2025 * | 299B 3.58B | Capitalization | 992B 11.88B |
|---|---|---|---|---|---|
| Net income 2024 * | 54.56B 653M | Net income 2025 * | 56.36B 675M | EV / Sales 2024 * | 3.3 x |
| Net cash position 2024 * | 72.7B 870M | Net cash position 2025 * | 112B 1.35B | EV / Sales 2025 * | 2.95 x |
| P/E ratio 2024 * |
18.1
x | P/E ratio 2025 * |
17.5
x | Employees | 25,863 |
| Yield 2024 * |
0.68% | Yield 2025 * |
0.71% | Free-Float | 91.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -1.54% | ||
| 1 week | -3.26% | ||
| Current month | -3.26% | ||
| 1 month | -5.21% | ||
| 3 months | +5.44% | ||
| 6 months | +7.45% | ||
| Current year | +2.75% |
1 week
5 937.65
6 189.00
1 month
5 937.656 335.00
Current year
5 520.656 505.90
1 year
4 384.056 505.90
3 years
3 654.006 505.90
5 years
2 351.206 505.90
10 years
1 872.956 505.90
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 73 | 07-06-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 5,957 | -1.54% | 597 736 |
| 24-04-16 | 6,050 | +0.66% | 408,298 |
| 24-04-15 | 6,011 | -1.20% | 269,933 |
| 24-04-12 | 6,084 | -1.20% | 394,851 |
| 24-04-10 | 6,158 | -0.16% | 196,084 |
Delayed Quote NSE India S.E., April 18, 2024 at 07:43 am EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-05-21
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
6,052
INR
Average target price
6,017
INR
Spread / Average Target
-0.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.00% | 676B | |
| +23.58% | 554B | |
| -7.67% | 349B | |
| +14.70% | 318B | |
| +6.58% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -12.07% | 144B |
- Stock Market
- Equities
- DRREDDY Stock
- DRREDDY Stock
